Study S002130

The Effect of Lixisenatide on Postprandial Lipid and Glucose Metabolism in Patients with Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT02049034
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 8
Start: 2014-01
Primary completion: 2016-01
Lead sponsor: University of Surrey
Conditions: Type 2 Diabetes
Interventions: OTHER:Lixisenatide; OTHER:Placebo
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: EUDRACT_NUMBER:2013-002826-22

Registered primary outcomes

Postprandial glucose kinetics [Two years]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0018624	Lixisenatide Reduces Chylomicron Triacylglycerol by Increased Clearance. Whyte MB, The Journal of clinical endocrinology and metabolism	2019	Randomized trial	PMID 30215735 DOI	cites ClinicalTrials.gov:NCT02049034; registry reference DERIVED:30215735